Vimarsana
Biggest News Aggregation in the World

Viz Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viz Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viz Platform Today - Breaking & Trending Today

Viz.ai, Inc.: Viz.ai Named to Forbes AI 50 List of Top Artificial Intelligence Companies of 2023 - Vimarsana News

Viz.ai, Inc.: Viz.ai Named to Forbes AI 50 List of Top Artificial Intelligence Companies of 2023

Only company in healthcare to be recognized for the fourth time Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been named to the 2023

Viz.ai, Inc.: Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm - Vimarsana News

Viz.ai, Inc.: Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

New artificial intelligence algorithm flags and triages suspected abdominal aortic aneurysms Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it

Viz.ai, Inc.: CORRECTING and REPLACING Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm - Vimarsana News

Viz.ai, Inc.: CORRECTING and REPLACING Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

New artificial intelligence algorithm flags and triages suspected abdominal aortic aneurysms Fourth paragraph, first sentence of release should read: Viz AAA uses artificial intelligence to automatically

Viz.ai, Inc.: Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial - Vimarsana News

Viz.ai, Inc.: Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial

Viz.ai's AI-powered clinical research platform will be used to find, screen and enroll patients in a landmark study of catheter-directed therapy for pulmonary embolism Viz.ai, the leader in AI-powered

Viz.ai, Inc.: Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM) - Vimarsana News

Viz.ai, Inc.: Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM Viz.ai, a leader in AI-powered disease detection